Lars V. Andreasen
Copenhagen, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.
Journal: Journal for immunotherapy of cancer
Published: May 01, 2024
First in man study: Bcl-Xl_42-CAF®09b vaccines in patients with locally advanced prostate cancer.
Journal: Frontiers in immunology
Published: December 13, 2022
Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.
Journal: Oncoimmunology
Published: January 17, 2022
Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial.
Journal: The Lancet. Infectious diseases
Published: December 19, 2016
First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12months and 5years of age.
Journal: Vaccine
Published: November 07, 2016
Aluminium hydroxide potentiates a protective Th1 biased immune response against polio virus that allows for dose sparing in mice and rats.
Journal: Vaccine
Published: October 02, 2014
Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.
Journal: PloS one
Published: April 08, 2014
Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant T cell epitopes: safety, immunogenicity, and feasibility in Guinea-Bissau.
Journal: AIDS research and human retroviruses
Published: May 03, 2013
Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection.
Journal: Clinical immunology (Orlando, Fla.)
Published: September 17, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026